Atai Life Sciences (Nasdaq:ATAI) announced inconclusive data regarding the effects of the kratom-derived compound KUR-101 on respiration in a Phase 1 study. The company’s stock was down about 9% in mid-day trading, trading at $2.77. The drug candidate yielded dose-dependent analgesic effects in Part 1 of the study, which assessed the safety and efficacy of various dose…
Meet the startup aiming to treat opioid use disorder with a kratom-derived drug
Atai Life Sciences (Nasdaq:ATAI) recently announced positive results from a Phase 1 study testing KUR-101 for opioid use disorder. KUR-101 is an oral formulation of the kratom alkaloid mitragynine. Atai subsidiary Kures is leading the effort to test the potential of mitragynine, which acts as a partial mu-opioid receptor agonist. Kratom itself is a source of controversy.…